Rosetta Posts Increased Revenues, Losses for 2014 | GenomeWeb

NEW YORK (GenomeWeb) – Rosetta Genomics reported today after the close of the market a 228 percent jump in 2014 revenues, derived primarily from the sale of its microRNA-based diagnostics.

The company's revenues from continuing operations jumped to $1.3 million last year from $405,000 the year before.

Rosetta's net loss after discontinued operations was $14.5 million, or $1.29 a share on 11.2 million shares outstanding, versus $12.9 million, or $1.34 a share, on 9.6 million shares outstanding, in 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.